Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5752W HIGH $16.45
Volume
109.83 K
Value Traded
193.68 K
Short % Float
1.43%
-2.91%Week
-5.44%1 Month
+26.72%3 Month
+261.99%6 Month
-79.24%5 Year
-79.24%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
364.41 M
EPS (TTM)
-0.28
P/E Ratio
-
Ent. Value
361.73 M
Total Shares
30.37 M
Float Shares
10.79 M
Insiders
63.78%
Institutions
4.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
TTRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Turn Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Turn Therapeutics Inc.
66Total events
10Upcoming
15Tier-1 (high impact)
2025 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲PublicationGX-03Presentation
Peer-reviewed publication of in-vivo study in Life showing GX-03 reduces IL-36, IL-31, IL-4
atopic dermatitissource ↗
▲Interim AnalysisGX-03Trial
Interim analysis of Phase 2 GX-03 atopic dermatitis trial completed
atopic dermatitissource ↗
◆Oral PresentationGX-03Presentation
Webcast presenting comprehensive interim analysis and optimized Stage 2 design for GX-03 in atopic dermatitis
atopic dermatitissource ↗
◆Interim AnalysisGX-03Trial
Comprehensive interim analysis of Stage 1 data from adaptive Phase 2 trial of GX-03
atopic dermatitissource ↗
◆Oral PresentationGX-03Presentation
Webcast presenting comprehensive interim analysis and optimized Stage 2 design for GX-03
atopic dermatitissource ↗
▲Protocol AmendmentGX-03Trial
Phase 2 GX-03 study expanded to enroll approximately 120-135 patients across broader disease extent
atopic dermatitissource ↗
◆Oral PresentationGX-03Presentation
Presentation of detailed findings at Jefferies Global Healthcare conference
moderate-to-severe atopic dermatitissource ↗
◆Topline ReadoutGX-03Clinical Data
Topline results expected for Phase 2 trial of GX-03 in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
▲Interim AnalysisGX-03Trial
Interim analysis findings from Phase 2 trial of GX-03 in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
▲PublicationGX-03Presentation
Peer-reviewed publication in Journal of Dermatological Treatment of preclinical GX-03 data showing reduced skin inflammation
skin inflammation (preclinical)source ↗
▲Preclinical PoCGX-03Preclinical
Preclinical study showed GX-03 significantly reduced skin inflammation in IL-36 animal model
skin inflammationsource ↗
●Oral PresentationPresentation
Turn Therapeutics to present at Jefferies Global Healthcare Conference 2026
●Management ChangeCorporate
Stephen M. Hahn, M.D., former FDA Commissioner, appointed Executive Clinical and Regulatory Lead
▼Equity OfferingCorporate
Initial Tranche of $7 Million Growth Capital Funded by Avenue Capital Group
◆Topline ReadoutGX-03Clinical Data
Phase 2 topline results for GX-03 in atopic dermatitis expected mid-2026
moderate-to-severe atopic dermatitissource ↗
◆Interim AnalysisGX-03Trial
Interim analysis for GX-03 Phase 2 AD trial
moderate-to-severe atopic dermatitissource ↗
◆Management ChangeCorporate
Appointments of Dr. Robert Redfield and Martin Dewhurst to leadership team
▲Partnership / LicenseCorporate
Global license, supply, and distribution agreement with Medline
●Type B MeetingGX-03FDA Meeting
Company advanced FDA Type B meeting package for GX-03
atopic dermatitissource ↗
▲Debt Royalty FinancingCorporate
Closed growth capital facility with Avenue Capital Group, initial $7 million tranche funded
▲Debt Royalty FinancingCorporate
Secured up to $25 million venture debt facility from Avenue Capital
●Management ChangeCorporate
Appointed Dr. Robert Redfield to provide strategic guidance on GX-03
●Pipeline PrioritizationCorporate
Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate
influenzasource ↗
▲Management ChangeCorporate
Appointment of Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
◆Oral PresentationPresentation
Presentation at 36th Annual Oppenheimer Healthcare Life Sciences Conference
◆Interim AnalysisGX-03Trial
Interim data expected for GX-03 phase 2 trial in atopic dermatitis
moderate-severe atopic dermatitissource ↗
◆Topline ReadoutGX-03Clinical Data
Topline data from lead program in severe eczema
severe eczemasource ↗
●Preclinical PoCPreclinical
In-vivo and in-vitro studies for influenza vaccine candidate expected to commence
influenzasource ↗
◆Management ChangeCorporate
Appointed Arthur Golden and Dr. Kent Kester to Board of Directors
▲Partnership / LicenseCorporate
Entered into global supply, development, and license agreement with Medline
◆Management ChangeCorporate
Appointment of Andrew Scott as Vice President of Corporate Communications
▲Partnership / LicenseCorporate
Global supply, development, and license agreement with Medline
●Quarterly UpdateCorporate
Shareholder webinar to review execution milestones, pipeline progress, and capital strategy
●Enrollment UpdateGX-03Trial
Approximately 25% of targeted sample size completed the trial
moderate to severe eczemasource ↗
▲Partnership / LicenseCorporate
Global supply, development, and license agreement with Medline
●Trial InitiationTrial
In-vivo studies scheduled to commence in Q4 2025
global health (thermostable intranasal vaccine)source ↗
▲First Patient DosedGX-03Trial
First patient enrolled in Phase 2 RCT for moderate to severe AD
moderate to severe atopic dermatitissource ↗
Past FDA Catalysts and PDUFA Decisions
How TTRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-01 | GX-03 (topical IL-36/IL-31 inhibitor) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$144M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.4x
rNPV / MCap
Top 46%
Micro Cap(rank 304 of 660)
Percentile Rank
Turn Therapeutics Inc. faces pipeline headwinds (38/100), with $361M risk-adjusted pipeline value, led by GX-03 in Eczema Atopic Dermatitis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GX-03 Small moleculeCompletedNCT04951349 | Covid19 | Phase 2 | COMPLETED | 85 | May 30, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every TTRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GX-03 | moderate-to-severe atopic dermatitis | Phase 2 | 2026-06-01 | EASI 50: 92.6%; EASI 75: 70.4%; EASI 90 (4 weeks): 44.4%; EASI 90 (8 weeks): 51.9%; vehicle EASI 50: 65.2%; vehicle EASI 90 (4 weeks): 30.4%; vehicle EASI 90 (8 weeks): 34.8%Read More | Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic DermatitisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Burnam Bradley EvanDirector, Officer (Chief Executive Officer), 10% Owner | Disposition | -300,000 15,116,260 held | $0.00 | 05/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TTRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TTRX for Q2 2026. | ||||
TTRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TTRX ranks across every disease it competes in
Competitive Position is a premium feature
See how TTRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTTRX News
TTRXTurn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Turn Therapeutics Inc. will present at the Stifel 2026 Virtual Immunology and Inflammation Forum. CEO Bradley Burnam and Executive Clinical Lead Stephen M. Hahn, M.D., will provide insights into their targeted therapies for inflammatory skin diseases. The event is scheduled for September 23, 2026, at 1:30 PM ET.
Read more →TTRX▲ +8.6%on this newsshared move
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
Turn Therapeutics Inc. has appointed Dr. Robert R. Redfield as Chief Scientific Officer. With over 40 years of experience in immunology and public health, Dr. Redfield is expected to enhance the company's research capabilities. His extensive background in infectious diseases and clinical research aligns with Turn Therapeutics' focus on targeted therapies for skin diseases.
Read more →TTRXTurn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Turn Therapeutics has published new peer-reviewed research demonstrating that its investigational therapy, GX-03, effectively reduces key inflammatory signals linked to skin diseases. The study, published in the journal Life, provides in-vivo evidence supporting the therapeutic potential of GX-03 in treating inflammatory skin conditions. This advancement highlights the company's focus on localized therapies.
Read more →TTRX▼ -6.5%on this news
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
Turn Therapeutics Inc. has announced its corporate updates and financial results for Q2 2026. The company highlighted a productive period, showcasing interim data from the GX-03 Phase 2 trial, which indicates activity across a broader range of conditions. This marks a significant development in their efforts to address inflammatory and infectious skin diseases.
Read more →TTRXTurn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
Turn Therapeutics Inc. will ring the Nasdaq Closing Bell on August 10, 2026, as a recognition of its achievements. CEO Bradley Burnam and the management team will participate in the event, which underscores the company's advancements in targeted therapies for inflammatory skin diseases. This invitation reflects Nasdaq's acknowledgment of Turn Therapeutics' progress.
Read more →TTRX▲ +26.3%on this news
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics has announced the final design for its Stage 2 program and a data-driven expansion of the GX-03 Phase 2 program targeting atopic dermatitis. The announcement indicates a strategic move to enhance the clinical development of their treatment. Further details on the specific data and design elements were not disclosed in the article.
Read more →TTRX▲ +26.3%on this newsshared move
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Turn Therapeutics is set to host a webcast to present a comprehensive interim analysis and the optimized design for Stage 2 of their GX-03 treatment for atopic dermatitis. This event aims to provide insights into the ongoing development and efficacy of the treatment. Further details will be shared during the webcast.
Read more →TTRX▼ -6.2%on this news· ran to -17% by day 3
Jefferies Global Healthcare Conference June 2026 2 Disclaimer Except for historical information set forth herein, the matters set forth in this presentation contain forward - looking statement s within the meaning of the
Turn Therapeutics presented at the Jefferies Global Healthcare Conference, discussing the innovative PermaFusion delivery platform and its applications in drug development. The company is focusing on precision immunomodulation therapies for inflammatory diseases, particularly moderate to severe atopic dermatitis, with its lead candidate GX-03 currently in Phase 2 trials. The presentation emphasized the zero reported adverse events and the patent protections surrounding their unique therapy approach. Future expectations include interim results of the ongoing clinical trials to assess efficacy and safety.
Read more →TTRX▲ +21.7%on this newsshared move
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
Turn Therapeutics has reported interim analysis findings from its Phase 2 GX-03 trial focused on moderate-to-severe atopic dermatitis. The company is implementing an adaptive optimization strategy based on these findings. Further details on the results and implications for the trial were not disclosed in the article.
Read more →TTRXTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Turn Therapeutics has announced a peer-reviewed publication in the Journal of Dermatological Treatment. The publication highlights the activity of GX-03 in an IL-36 associated inflammatory model. This development may contribute to the understanding of treatments for inflammatory skin conditions.
Read more →TTRX▼ -7.1%on this news
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Turn Therapeutics is set to present at the Jefferies Global Healthcare Conference in 2026. The announcement highlights the company's participation in a significant industry event, which may provide opportunities for networking and showcasing their developments.
Read more →TTRX▲ +21%on this newsshared move
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics has appointed Dr. Stephen M. Hahn as its Executive Clinical and Regulatory Lead. Dr. Hahn, a physician-scientist and former FDA Commissioner, is expected to leverage his expertise to guide the company's clinical and regulatory strategies. This strategic appointment aims to strengthen Turn Therapeutics' position in the biopharma sector.
Read more →TTRXTurn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics has released its financial results for the first quarter of 2026, showcasing a net loss while highlighting significant corporate developments. The company secured $7 million as part of a larger $25 million growth capital funding from Avenue Capital Group. Their lead product, GX-03, is undergoing a Phase 2 trial for moderate-to-severe atopic dermatitis, with topline results expected in mid-2026, which could influence the company's future strategy. The Phase 2 trial remains on track with an upcoming interim analysis, highlighting the focus on advancing their clinical pipeline despite financial challenges.
Read more →TTRXTurn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. reported its financial results for 2025 and provided updates on its clinical programs. The company is on track with its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, expecting topline results in mid-2026. Additionally, it secured up to $25 million in growth capital and strengthened its leadership team.
Read more →TTRXTurn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics has secured financing of up to $25 million from Avenue Capital Group. This funding aims to support the company's ongoing projects and initiatives. The terms of the financing have not been disclosed in detail, but it marks a significant step for Turn Therapeutics in its financial strategy.
Read more →About Turn Therapeutics Inc.
Headquarters250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE, CA, 91362
BIOPHARMAWATCH ELITE PLUS
Trade the next TTRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime